

# **Dose Individualization for Cancer Chemotherapy**

**Gary Rosner**

**Department of Biostatistics**

**U.T. M.D. Anderson Cancer Ctr**

**PODE Workshop**

**June 2009**

# The Motivating Problem

- Dr. Borje Andersson @ MDACC
  - Ultra high-dose therapy to treat leukemia
    - Dose too high?
      - Fatal toxicity
    - Dose too low?
      - Less chance for benefit
    - Solution
      - Choose “optimal” dose

# Bayesian Modeling

- **Incorporates prior info**
  - Previous studies
  - “Expert” opinion
- **Predict & estimate precision**
  - Based on current knowledge
    - Can incorporate information from outside of current study

# Optimal Individualized Dose

- Jelliffe et al.
- D'Argenio & Rodman
- Wakefield
  - Constant & quadratic loss functions
- Sandstrom, Karlsson, Ljungman, et al.
  - Individualization of oral busulfan

# Back to Transplant Study

- **Have previous studies**
  - 1/day dosing & 2/day dosing
- **Current study**
  - 12 mg i.v. test dose
  - Uniform high dose (mg/m<sup>2</sup>)
- **Future study**
  - Test dose ⇒ PK ⇒ “Optimal”

# What We Would Like To Do

- **Combine**
  - Meta-analysis of PK from earlier studies
  - PK of test dose for new patient
- **Predict PK for new patient**
  - Determine optimal dose
    - Bayesian Decision Theory

# Data

Study	Pt. #	Dose	Time	Conc	Covar
1	1	HIGH	$t_{1,1,1}, \dots$	$y_{1,1,1}, \dots$	$x_{1,1}, \dots$
...	...	...	...	...	...
1	i	HIGH	$t_{1,i,j}, \dots$	$y_{1,i,j}, \dots$	$x_{1,i}, \dots$
...	...	...	...	...	...
1	$n_1$	HIGH	$t_{1,n_1,j}, \dots$	$y_{1,n_1,1}, \dots$	$x_{1n_1}, \dots$
2	1	low	$t_{2,1,1}, \dots$	$y^*_{2,1,1}, \dots$	$x_{2,1}, \dots$
2	1	HIGH	$t_{2,1,1}, \dots$	$y_{2,1,1}, \dots$	$x_{2,1}, \dots$
...	...	...	...	...	...
2	i	low	$t_{2,i,1}, \dots$	$y^*_{2,i,1}, \dots$	$x_{2,i}, \dots$
2	i	HIGH	$t_{2,i,1}, \dots$	$y_{2,i,1}, \dots$	$x_{2,i}, \dots$
...	...	...	...	...	...
2	$n_2$	low	$t_{2,n_2,1}, \dots$	$y^*_{2,n_2,1}, \dots$	$x_{2,i,n_2}, \dots$
2	$n_2$	HIGH	$t_{2,n_2,1}, \dots$	$y_{2,n_2,j}, \dots$	$x_{2,n_2}, \dots$
3	1	low	$t_{3,1,1}, \dots$	$y^*_{3,1,1}, \dots$	$x_{3,1}, \dots$

# Sampling Distribution Nonlinear Mean Function

- For pt.  $i$ , in study  $s$ , at time  $t_{sij}$

$$\begin{aligned}y_{s,i,j} &= \log [\text{Conc}(t_{s,i,j})] \\&= \log [f(t_{s,i,j})] + error\end{aligned}$$

# Population Model as Hierarchical Model

- **Observation**

$$p(y_{s,i,j} \mid \theta_i), s = 1, \dots, S; j = 1, \dots, n_i$$

- **Subject-specific parameters**

$$p(\theta_i \mid \phi), i = 1, \dots, I$$

- **Population**

$$p(\phi)$$

# Mixture Models for Population Distribution

- **Distribution of subject-specific parameters:**

$$p(\theta_i \mid \phi), i = 1, \dots, I$$


- **Characterize as a mixture of simpler distributions**

- **Weighted sum of densities**

$$\begin{aligned} p(\theta_i \mid \phi) &= \text{Mixture of MV Normals} \\ &= \sum_k w_k N(\mu_k, V) \end{aligned}$$

# Why Mixture?

- **Flexible: Depict Many Shapes**
  - **Heterogeneity:**
    - patient characteristics
    - genetic diversity
- **Example:**
  - **Mixtures of normal densities (kernels)**



# Dirichlet Process (DP)

## *Mixture of Normals*

- Dirichlet Process is distribution on space of distributions
- DP has 2 parameters
- $G_0$  is base measure
- $M$  is total mass parameter

$$\mu_i \sim G$$

$$G \sim DP(G_0, M) \quad i.e., G = \sum_{h=1}^{\infty} w_h \delta(\mu_h)$$

$$G_0(\mu) = N(b, B)$$

# Hierarchical Model: Within Study

$$\log(y_{ij}) = \log[f(\theta_i, t_{ij})] + \varepsilon_{ij}$$





$$\varepsilon_{ij} \sim N(0, \tau^{-1}), \quad \tau \sim Ga(\alpha_\tau, \beta_\tau)$$

$$\left. \begin{array}{l} \theta_i \sim N(\mu_i, S) \\ \mu_i \sim G \end{array} \right\} \Rightarrow \theta_i \sim \sum_{h=1}^{\infty} w_h N(\mu_h, S)$$

$$G \sim DP(G_0, m) \quad i.e., G = \sum_{h=1}^{\infty} w_h \delta(\mu_h)$$

# Multiple Studies Hyperprior for Meta-Analysis

- **Straightforward if parametric hyperprior (random effects)**
  - Parametric model provides structure
- **Complex if mixture hyperprior**
  - Link studies at what level?
  - How enforce linkage?



# How Model Commonality?

# Want to Share More Info From Prior Studies

- **Dependent Dirichlet Process**
  - ANOVA-like structure for means
    - Categorical covariates:  $x = (v, w)$ 
      - Locations linked across factor levels of  $x$  via ANOVA model

$$G_x(\phi) = \sum w_h \delta(m_{xh}),$$

$$m_{xh} = \mu_h + A_{v,h} + B_{w,h}$$

# Dependence Structure

## DP Mixture of ANOVA (categorical)

- **Across levels of  $x$  (C levels)**

$$x = x_1, x_2, \dots, x_C$$

$$x = x_1 : G_{x_1} = \omega_1 \delta(m_{11}) + \omega_2 \delta(m_{12}) + \omega_3 \delta(m_{13}) + \dots$$

$$x = x_2 : G_{x_2} = \omega_1 \delta(m_{21}) + \omega_2 \delta(m_{22}) + \omega_3 \delta(m_{23}) + \dots$$


$$x = x_3 : G_{x_3} = \omega_1 \delta(m_{31}) + \omega_2 \delta(m_{32}) + \omega_3 \delta(m_{33}) + \dots$$

...





- **Locations are functions of  $x$**

$$m_{xh} = \mu_h + A_{v,h} + B_{w,h}$$

# 2 Factors, 2 Levels Each:



# Compare Mixture to ML Estimation



# Covariates

- **Dependent Dirichlet Process (DDP)**
  - Decompose locations as sums of random measures
- **Categorical covariates**
  - ANOVA DDP
    - Two factors  $v$  and  $w$ :  $x = (v, w)$   
 $m_{xh} = \mu_h + A_{v,h} + B_{w,h}$
- **Categorical & continuous covariates**
  - Linear DDP
    - One categorical & 1 continuous  $x = (v, z)$   
 $m_{xh} = \mu_h + A_{vh} + \beta_h z$

# Back to Transplant Study


- **Multiple studies**
  - **Hierarchical extension**
    - **$G$  is 2x3 matrix-variate dist'n**

$$\theta_{ki} \sim \int N(\mu_{ki}, S) dG_{ki}(\mu_{ki}), k = 1, 2, 3$$




$$A \sim G$$

$$A = [m, ST_2, ST_3] = \begin{pmatrix} \text{Main} & \text{Study2} & \text{Study3} \\ \log V_0 & \log V_2 & \log V_3 \\ \log k_0 & \log k_2 & \log k_3 \end{pmatrix}$$

# Have 2 Studies



# Fitted Profiles




Incorporate  
Test Dose


# Back to Transplant Example

- **Have**
  - Model for drug's PK
  - Probability model for data
- **Need utility function to optimize**

# Dose Optimization



AUC too low!



AUC too high!



# Bayesian Optimal Design

- **Let**  $u(y,d,\theta) = L(AUC)$ ,  $AUC = f(d,V,k)$

- **Pick dose  $d^*$  that minimizes**


$$E[u(y,d,\theta)] = \iint u(y,d,\theta) p_d(y,\theta) dy d\theta$$

- **With data:**
  - Studies 1 & 2 plus new patient's low dose data

$$E[u(y,d,\theta)] = \int L[AUC(\theta,d)] p(\theta|D) d\theta$$

# Asymmetric Loss Function

- Want AUC in “optimal” range




- Loss function

$$L(auc) = \begin{cases} L^-(auc, AUC_{ll}) & \text{if } auc < AUC_{ll} \\ 0 & \text{if } AUC_{ll} < auc < AUC_{ul} \\ L^+(auc, AUC_{ul}) & \text{if } auc > AUC_{ul} \end{cases}$$


# For Study 3: Posterior for this patient's PK parameters

Third Study




# Optimal Dose w.r.t. Posterior

Loss Function



Expected Loss



# Summary

- Mixture models
  - flexible inference
- DDP structure
  - Categorical and continuous covariates
- Optimal design for PK
- Currently evaluating our strategy against covariate-based dosing

# Спасибо